Is there a role for pleiotropic effects of atorvastatin and fenofibrate in the metabolic syndrome and prediabetes?
Evaluation of: Krysiak R, Gdula-Dymek A, Bachowski R, Okopien B. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of prediabetes. Diabetes Care 33(10), 2266-2270 (2010). The beneficial use of fibrates and statins has been observed in previous studies among patients with dyslipidemia, including those with glucose metabolism abnormalities. The paper under evaluation highlights these benefits and provides insight. Specifically, these findings are observed in patients who have prediabetes and metabolic syndrome (MS), and are taking atorvastatin or fenofibrate. The paper documents that both drugs have multiple pleiotropic effects on MS patients. Furthermore, these effects may be determined by prediabetes type. The results strengthen previous knowledge and offer new understanding, as no previous study has investigated whether the type of prediabetes can determine extra-lipid effects and cardiovascular risk factors in MS patients.